Search research articles
Contact Us
Filters
Showing results (121-130 of 531) with videos related to
Page
of 54
Sort By:
Antimicrobial Agents and Chemotherapy
|
September 10, 2009
In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model
Céline Vidaillac, Steve N Leonard, Michael J Rybak
Pharmacotherapy
|
February 2, 2023
Oral stepdown in Gram-positive bloodstream infections: A step in the right direction
Kaylee E Caniff, Nicholas Rebold, Michael J Rybak
Pharmacotherapy
|
September 6, 2019
Parenteral Fosfomycin for the Treatment of Multidrug Resistant Bacterial Infections: The Rise of the Epoxide
Trang D Trinh, Jordan R Smith, Michael J Rybak
Antimicrobial Agents and Chemotherapy
|
July 2, 2008
Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations
Warren E Rose, Steven N Leonard, Michael J Rybak
Pharmacotherapy
|
February 24, 2001
Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam
T K Jellison, P S Mckinnon, M J Rybak
Antimicrobial Agents and Chemotherapy
|
June 1, 1992
Absence of "red man syndrome" in patients being treated with vancomycin or high-dose teicoplanin
M J Rybak, E M Bailey, L H Warbasse
Antimicrobial Agents and Chemotherapy
|
August 1, 1991
Clinical evaluation of teicoplanin fluorescence polarization immunoassay
M J Rybak, E M Bailey, V N Reddy
The Annals of Pharmacotherapy
|
October 1, 1993
Enterococcus, an emerging pathogen
S A Tailor, E M Bailey, M J Rybak
Antimicrobial Agents and Chemotherapy
|
June 1, 1997
Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium
R C Mercier, H H Houlihan, M J Rybak
Pharmacotherapy
|
January 10, 2019
The Optimal Use of the Polymyxins Before Their Time Is Up
Sara Alosaimy, Sarah C J Jorgensen, Michael J Rybak
Page
of 54
Search research articles
Search
Showing results (121-130 of 531) with videos related to
Sort By:
Page
of 54
Antimicrobial Agents and Chemotherapy
|
September 10, 2009
In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model
Céline Vidaillac, Steve N Leonard, Michael J Rybak
Pharmacotherapy
|
February 2, 2023
Oral stepdown in Gram-positive bloodstream infections: A step in the right direction
Kaylee E Caniff, Nicholas Rebold, Michael J Rybak
Pharmacotherapy
|
September 6, 2019
Parenteral Fosfomycin for the Treatment of Multidrug Resistant Bacterial Infections: The Rise of the Epoxide
Trang D Trinh, Jordan R Smith, Michael J Rybak
Antimicrobial Agents and Chemotherapy
|
July 2, 2008
Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations
Warren E Rose, Steven N Leonard, Michael J Rybak
Pharmacotherapy
|
February 24, 2001
Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam
T K Jellison, P S Mckinnon, M J Rybak
Antimicrobial Agents and Chemotherapy
|
June 1, 1992
Absence of "red man syndrome" in patients being treated with vancomycin or high-dose teicoplanin
M J Rybak, E M Bailey, L H Warbasse
Antimicrobial Agents and Chemotherapy
|
August 1, 1991
Clinical evaluation of teicoplanin fluorescence polarization immunoassay
M J Rybak, E M Bailey, V N Reddy
The Annals of Pharmacotherapy
|
October 1, 1993
Enterococcus, an emerging pathogen
S A Tailor, E M Bailey, M J Rybak
Antimicrobial Agents and Chemotherapy
|
June 1, 1997
Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium
R C Mercier, H H Houlihan, M J Rybak
Pharmacotherapy
|
January 10, 2019
The Optimal Use of the Polymyxins Before Their Time Is Up
Sara Alosaimy, Sarah C J Jorgensen, Michael J Rybak
Page
of 54